10

  Now, it was bad enough that someone else, some upstart immune to acquisition,  had triggered the next phase of evolution for the search engine, and that they had done so in a highly public way that captured the imagination of everyone from industry leaders to the tech-avoidant. The real twist of the knife came unexpectedly from Microsoft. Calling Bing a “rival” to Google Search is perhaps too generous — with about 3% of global search compared to Google’s 92%, Bing is more of a well-heeled gadfly. Microsoft seems to have abandoned any illusions about Bing’s ability to improve its standing, and looked outside their own house for help. Whether their investment in OpenAI was preternatural foresight or fortunate serendipity, at some point it became clear that they had backed a fast horse. Perhaps in some smoke-filled room, Satya Nadella and Sam Altman conspired to exclude Google from their new world order, but in public the conversation took the form of money, and lots of it. Wha...

  It is also indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ZUMA-3 is an ongoing international single-arm, open-label, registrational phase I/II study of Tecartus in adult patients (≥18 years old) with ALL whose disease is refractory to or has relapsed following standard systemic therapy or hematopoietic stem cell transplantation. The primary endpoint is the rate  of overall complete remission (CR) or complete remission with incomplete hematological recovery by central assessment . The secondary endpoints are duration of remission and relapse-free survival, overall survival, minimal residual disease (MRD) negativity rate and alloSCT rate. The three-year follow-up results showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell ALL, with a consistent safety profile observed since the two-year analysis.